Serum angiopoietin is associated with lung function in patients with asthma: a retrospective cohort study

BMC Pulmonary Medicine

An-Soo Jang²  Choon-Sik Park²  Sung-Woo Park²  PuReun-HaNeul Lee¹  Kuk-Young Moon¹ 

[1] Genome Research Center for Allergy and Respiratory Diseases, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon, Gyeonggi-do 420-767, Republic of Korea;Department of Internal Medicine, Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon, Gyeonggi-Do 420-767, South Korea

关键词: Asthma;    Angiopoietin-2;    Angiopoietin-1;    Angiogenesis;   

Others  :  1109532
DOI  :  10.1186/1471-2466-14-143

 received in 2014-03-23, accepted in 2014-08-18,  发布年份 2014

【 摘 要 】

Background

Angiopoietin-1 (Ang-1) is an essential mediator of angiogenesis that establishes vascular integrity, and angiopoietin-2 (Ang-2) acts as its natural inhibitor. We considered that angiopoietin might be important in bronchial asthma.

Methods

In total, 35 patients with asthma and 20 healthy subjects were studied.

Results

The serum Ang-1 levels were significantly elevated in patients with asthma compared to control subjects (293.9 ± 13.8 pg/mL vs. 248.3 ± 16.2 pg/mL, respectively, p = 0.04). The serum Ang-2 levels were not different between the two groups. The areas under the curve (AUC) for serum angiopoietins revealed that the serum level of Ang-1 (0.68) was more sensitive and specific than the serum Ang-2 level (0.55) for differentiating between patients with asthma and control subjects. The serum Ang-1/Ang-2 ratio was correlated with the FEV1/FVC ratio (r = -0.312, p = 0.02), while serum Ang-2 was correlated with body mass index.

Conclusions

Our results indicate that the serum Ang-1 levels were higher in asthma patients compared with healthy subjects. As the Ang-1/Ang-2 ratio was related to lung function, the data suggest that serum angiopoietin is associated with lung function in patients with asthma.

【 授权许可】

   
2014 Moon et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Corrigan CJ, Wang W, Meng Q, Fang C, Wu H, Reay V, Lv Z, Fan Y, An Y, Wang YH, Liu YJ, Lee TH, Ying S: T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A 2011, 108:1579-1584.
• [2]Al-Muhsen S, Johnson JR, Hamid Q: Remodeling in asthma. J Allergy Clin Immunol 2011, 128:451-462.
• [3]Kristan SS, Malovrh MM, Silar M, Kern I, Flezar M, Kosnik M, Suskovic S, Korosec P: Airway angiogenesis in patients with rhinitis and controlled asthma. Clin Exp Allergy 2009, 39:354-360.
• [4]Li X, Wilson JW: Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 1997, 156:229-233.
• [5]Hoshino M, Takahashi M, Aoike N: Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001, 107:295-301.
• [6]McDonald DM: Angiogenesis and remodelling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001, 164:39-45.
• [7]Puxeddu I, Berkman N, Nissim Ben Efraim AH, Davies DE, Ribatti D, Gleich GJ, Levi-Schaffer F: The role of eosinophil major basic protein in angiogenesis. Allergy 2009, 64:368-374.
• [8]Detoraki A, Granata F, Staibano S, Rossi FW, Marone G, Genovese A: Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 2010, 65:946-958.
• [9]Burgess JK, Boustany S, Moir LM, Weckmann M, Lau JY, Grafton K, Baraket M, Hansbro PM, Hansbro NG, Foster PS, Black JL, Oliver BG: Reduction of Tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness. Am J Respir Crit Care Med 2010, 181:106-115.
• [10]Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005, 9:267-285.
• [11]Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP: Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46.
• [12]Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, Papapetropoulos A: Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005, 314:738-744.
• [13]Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B, Mostoslavsky G, Ingber DE, Sukhatme VP: Angiopoietin-1 requires P190RhoGAP to protect against vascular leakage in vivo. J Biol Chem 2007, 282:23910-23918.
• [14]Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, azer N, Holash J, McDonald DM, Yancopoulos GD: Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-463.
• [15]Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C: Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005, 111:97-105.
• [16]Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are contextdependent regulators of vascular remodelling. Exp Cell Res 2006, 312:630-641.
• [17]Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG: The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
• [18]Kranidioti H, Orfanos SE, Vaki I, Kotanidou A, Raftogiannis M, Dimopoulou I, Kotsaki A, Savva A, Papapetropoulos A, Armaganidis A, Giamarellos-Bourboulis EJ: Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes. Immunol Lett 2009, 125:65-71.
• [19]Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, Chung LP: The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to nonsmall cell lung carcinomas. Lung Cancer 2000, 29:11-22.
• [20]Tseliou E, Bakakos P, Kostikas K, Hillas G, Mantzouranis K, Emmanouil P, Simoes D, Alchanatis M, Papiris S, Loukides S: Increased levels of angiopoietins 1 and 2 in sputum supernatant in severe refractory asthma. Allergy 2012, 67:396-402.
• [21]Makinde TO, Agrawal DK: Increased expression of angiopoietins and Tie2 in the lungs of chronic asthmatic mice. Am J Respir Cell Mol Biol 2011, 44:384-393.
• [22]Kanazawa H, Asai K, Tochino Y, Kyoh S, Kodama T, Hirata K: Increased levels of angiopoietin-2 in induced sputum from smoking asthmatic patients. Clin Exp Allergy 2009, 39:1330-1337.
• [23]Global Initiative for Asthma (GINA): Global strategy for Asthma Management and Prevention. NHLBI/WHO workshop report. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995. NIH publication no. 95-3659
• [24]Park SW, Lee YM, Jang AS, Lee JH, Hwangbo Y, Kim DJ, Park CS: Development of chronic airway obstruction in patients with eosinophilic bronchitis: a prospective follow-up study. Chest 2004, 125:1998-2004.
• [25]Park CS, Kim YY, Kang SY: Collection between RAST and skin test for inhalant offending allergens. J Korean Soc Allergol 1983, 3:1-9.
• [26]Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF: Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006, 355(8):763-778.
• [27]McGee DL: Body mass index and mortality: a meta-analysis based on personlevel data from twenty-six observational studies. Ann Epidemiol 2005, 15:87-97.
• [28]Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288:1723-1727.
• [29]Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
• [30]Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
• [31]Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
• [32]McDonald DM: Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am J Respir Crit Care Med 2001, 164(10 Pt 2):S39-S45.
• [33]Simon MP, Tournaire R, Pouyssegur J: The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol 2008, 217:809-818.
• [34]Thurston G: Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003, 314:61-68.
• [35]Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
• [36]Salvato G: Quantitative and morphological analysis of the vascular bed in ronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001, 56:902-906.
• [37]Hashimoto M, Tanaka H, Abe S: Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 2005, 127:965-972.
• [38]Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A: Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998, 158:153-156.
• [39]Paredi P, Kharitonov SA, Barnes PJ: Faster rise of exhaled breath temperature in asthma: a novel marker of airway inflammation? Am J Respir Crit Care Med 2001, 165:181-184.
• [40]Paredi P, Barnes PJ: The airway vasculature: recent advances and clinical implications. Thorax 2009, 64:444-450.
• [41]Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I, Sotiropoulou C: Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 2006, 35:199-206.
• [42]van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VWM, Groeneveld ABJ: Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008, 63:903-909.
• [43]Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A: Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am J Respir Crit Care Med 2008, 177:1314-1321.